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East Coast Fever (ECF), caused by the tick-borne apicomplexan parasite Theileria parva,
is a leading cause of morbidity and mortality in cattle of sub-Saharan Africa. The infection
and treatment method (ITM) is currently the only vaccine available to control T. parva.
Although ITM elicits levels of protection, its widespread adoption is limited by costs,
laborious production process, and antibiotic co-treatment requirement, necessitating the
development of a more sustainable vaccine. To this end, efforts have been concentrated
in the identification of new T. parva vaccine antigens and in the development of suitable
platforms for antigen expression. In this study, we investigated the molecular and
antigenic properties of T. parva antigen Tp9 expressed by mammalian cells. Data indicate
that Tp9 contains a signal peptide that is weakly functional in mammalian cells. Thus, Tp9
secretion from mammalian cells increased 10-fold after the native signal peptide was
replaced with the human tissue plasminogen activator signal peptide (tPA). Sera from all
T. parva-immune cattle recognized this recombinant, secreted Tp9. Additionally, PBMC
from ITM-immunized cattle produced significant (p < 0.05) amounts of IFNγ following ex
vivo exposure to Tp9, but this response varied between cattle of different MHC class
I and class II genotypes. In addition, depletion experiments demonstrated that IFNγ
to Tp9 was primarily produced by CD4+ T cells. Molecular analysis demonstrated that
Tp9 presents a signal peptide that is weakly functional in mammalian cells, suggesting
that it remains within lymphocytes during infection. Tp9 secretion from mammalian cells
was substantially increased when the tPA secretion signal sequence was substituted for
the native secretion signal sequence. Using full-length, recombinant Tp9 secreted from
mammalian cells, we demonstrated that T. parva-immune cattle develop both humoral
and cellular immune responses to this antigen. Collectively, these results provide rationale
for further evaluation of Tp9 as a component of a T. parva subunit vaccine.
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Bastos et al. Theileria parva Antigen 9 Characterization
INTRODUCTION
Theileria parva, a tick-borne protozoan parasite of the phylum
Apicomplexa and the causative agent of East Coast Fever
(ECF), kills over a million cattle each year in Eastern, Central,
and Southern Africa (1, 2). T. parva has a complex life
cycle that involves the development of asexual stages in the
bovine host and sexual stages in the tick vector, Rhipicephalus
appendiculatus. T. parva sporozoites, present in infected tick
salivary glands, are inoculated into cattle during tick feeding.
At this point, sporozoites rapidly enter B and T lymphocytes,
and develop into the schizont stage (3, 4). Schizonts induce
neoplasia-like transformation of infected lymphocytes, and
divide in concert with the transformed cells. Clonal expansion
of infected cells, and the resultant immune response, leads to
clinical signs of ECF, including lymphadenopathy, leukopenia,
thrombocytopenia, fever, respiratory failure, and death (5).
Control of T. parva currently relies on extensive use
of acaricides to limit tick infestation and on the infection
and treatment method (ITM) of immunization, in which
cattle are infected via subcutaneous inoculation of live T.
parva sporozoite stabilate and co-treated with long-acting
oxytetracycline. The use of acaricides has major drawbacks,
including the development of resistant tick populations, food-
safety concerns, and environmental contamination resulting
from toxic residues (6). Although ITM elicits long-lived T.
parva immunity, vaccine stabilate production is labor-intensive
and expensive. Determination of sporozoite dose is difficult to
standardize and requires large numbers of cattle to titrate each
batch of vaccine. Vaccine costs are further increased by the
requirement for oxytetracycline co-treatment, and these costs
are often prohibitive to smallholder pastoralist farmers who
are in greatest need of the vaccine (7, 8). In addition, ITM-
immunized animals remain life-long, asymptomatic carriers of
T. parva, which poses risk for the spread of the disease to non-
immunized animals via tick bite (8, 9). Therefore, development of
a next-generation vaccine to control T. parva is urgently needed.
It has been demonstrated that the protective immune response
against T. parva requires development of a CD8+ T-cell response
to schizont-infected lymphocytes (10–12). It has also been shown
experimentally that induction of a robust antibody response
to a recombinant sporozoite surface antigen, p67, can provide
protection in a proportion of animals by preventing or reducing
the entry of sporozoites into bovine lymphocytes (13–16). The
immunogenic potential of another antigen, the polymorphic
immunodominant molecule (PIM), has also been examined. PIM
is expressed by both sporozoite and schizont stages of the parasite
(17), but although it has been shown to induce both cellular and
humoral immune responses, there is yet no evidence that it can
stimulate immunity (16). An additional eight antigens, named
Tp1-8, were identified as targets of MHC class I-restricted CD8+
T lymphocytes from T. parva-immune cattle (10). Subsequently,
a further three antigens, named Tp9, Tp10, and Tp12, were also
identified by screening CD8+ T cell lines from immune cattle
(18, 19). Despite the fact that a subset of these antigens have
been tested for immunogenicity (10), further studies are needed
to fully evaluate their potential as vaccine candidates.
Concomitantly with the identification of novel antigens was
extensive work to optimize antigen expression systems and
delivery platforms for Theileria antigens. Both prokaryotic and
eukaryotic systems have been tested for expression of potential
T. parva vaccine antigens (15, 16, 20, 21). Codon usage, post-
translational modifications, protein conformation, and solubility
are a few aspects that have been considered in deciding the
most suitable platform to express antigens for subunit vaccines.
Recently, we examined the antigenicity of the full-length T.
parva p67 protein expressed in a mammalian system, and that
work provided a basis for further studies to investigate this
recombinant, mammalian expressed antigen as a subunit vaccine
component to prevent T. parva (21).
In the present study, we consider the hypothesis that a suitable
platform to express T. parva vaccine antigens will maintain the
antigenic properties of the native target protein. To this end, we
expressed Theileria parva antigen Tp9 in a mammalian system
and characterized its molecular and antigenic properties. We
demonstrate that native Tp9 is poorly secreted from mammalian
cells and likely remains within lymphocytes during infection. Its
secretion was considerably augmented by replacing the native
signal peptide by a canonical eukaryotic signal peptide. Using
the recombinant, mammalian-expressed and secreted Tp9, we
showed that T. parva-immune cattle develop both humoral and
cellular immune responses to this antigen. We also developed
several human and bovine-derived cell lines transduced by a
third-generation lentiviral vector that constitutively express a
stable and secreted Tp9 form that can be useful for diagnostic
and immunization purposes. Collectively, these results establish
a rationale for the use of the mammalian expressed Tp9 as a
component of a subunit vaccine to control ECF.
MATERIALS AND METHODS
Mammalian Cell Lines
Human Embryo Kidney (HEK) 293T (ATCC: CRL-11268),
Madin Darby Canine Kidney Cells (MDCK, ATCC R© CCL-
34TM) and Swine kidney epithelial cells (PK15, ATCC R© CCL-
33 R©) were maintained as suggested by the manufacturer’s
instructions. Equine Adipose-Derived Stromal Cells (EADSC),
Bovine Bone Marrow Stromal Cells (BBMSC), and Alpaca
derived Skin Stromal cells (ADSSC) were derived, immortalized,
and maintained as previously described (22–24). All cell
lines were cultured in Eagle’s Minimal Essential Medium
(EMEM, Gibco) containing 10% fetal bovine serum (FBS),
2mM of L-glutamine (Gibco), 100 IU/mL of penicillin (Gibco),
100µg/mL of streptomycin (SIGMA), and 0.25µg/mL of
amphotericin B (Gibco) and were incubated at 37◦C/5% CO2 in
a humidified incubator.
Sequence Analysis and Cloning of Tp9
The codon-usage adapted Tp9 synthetic ORF was constructed
from a published sequence (NCBI GenBank: JQ735949.1)
(Supplementary Figure 1). In this synthetic construct, the
natural predicted signal peptide was substituted with human
tissue plasminogen activator signal peptide (tPA). In order to
provide the natural Tp9 signal peptide (tp9SP), insert a NheI
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restriction site at the 5’ terminus of the ORF, tag Tp9 ORF
with the peptide epitope AU1 (DTYRYI) (25), and insert a SmaI
restriction site at 3′ terminus, the tp9 ORF was amplified using
PCR with a pTp9 DNA template and Tp9SP-Tp9 sense and
Tp9 AU1 antisense primers (Supplementary Table 1). The PCR
amplification reaction was performed in a final volume of 50
µl, containing 10mM Tris–hydrochloride pH 8.3, 10% Dimethyl
Sulfoxide (DMSO), 0.2mM deoxy nucleotide triphosphates,
2.5mM MgSO, 50mM KCl, and 0.25µM of each primer. pTP9
DNA was firstly linearized with PstI to facilitate polymerase
action and then amplified over 35 cycles, each cycle consisting
of 1min of denaturation at 94◦C, 1min of primer annealing
at 58◦C and 1min of chain elongation with 1U of Pfu DNA
polymerase (Thermo Fisher Scientific) at 72◦C. The amplicon
was subsequently checked in 1% agarose gel and visualized
after ethidium bromide staining in 1X TAE buffer (40mM Tris-
acetate, 1 mM EDTA).
pCMV-Tp9AU1 was generated by sub-cloning the amplified
tp9sp-Tp9 ORF, cut withNheI/SmaI restriction enzymes, into the
shuttle vector pINT2EGFP (26). It was then digested with the
same enzymes to excise the EGFP ORF and put the Tp9 ORF
under the transcriptional control of the strong Cytomegalovirus
immediate early gene promoter and of the bovine growth
hormone polyadenylation signal.
Full length Tp9 deprived of its signal peptide was
obtained using PCR starting from the pTP9 DNA template
using a Tp9 sense and Tp9 AU1 antisense primer pair
(Supplementary Table 1) to insert a NheI restriction site at
the 5′ terminus and a SmaI restriction site at the 3′ terminus with
the AU1 tag. PCR amplification of this construct was performed
as described above with the same parameters. TheNheI/SmaI cut
amplicon was cloned into the shuttle vector pINT2EGFP (26)
and cut with the same enzymes to generate pCMV-1spTp9AU1.
The natural Tp9 signal peptide was also placed in front
of the EGFP ORF through EGFP PCR amplification using
the Tp9SP-GFP sense and GFP-AU1 antisense primer pair
(Supplementary Table 1). pEGFPC1 DNA (Clontech) was firstly
linearized with AseI and then used as a template to amplify
the EGFP ORF with the natural Tp9 signal peptide and a
NheI restriction site at the 5’ terminus and the AU1 tag and
a XhoI restriction site at the 3’ terminus. This amplicon was
cut with NheI/XhoI and cloned into pEGFP-C1, in which the
EGFP ORF was excised with the same restriction enzymes, to
generate pCMV-Tp9spGFP.
Using PCR amplification, the tPA signal peptide was added to
the Tp9 ORF (tPA-sp). Starting from the pTp9 DNA template,
the SmaI-NheI Tp9 sense and Tp9 AU1 antisense primer pair
(Supplementary Table 1) was used to insert the tPA signal
peptide and NheI restriction site at the 5′ terminus and a
SmaI restriction site at the 3′ terminus with an AU1 tag.
The amplicon was restriction digested with NheI/SmaI and
ligated into NheI/SmaI cut pINT2EGFP to generate pCMV-
tPAspTp9AU1.
The lentiviral transfer vector pEF1α-tPA-Tp9-iresGFP,
delivering full length tPA-Tp9AU1 with a tPA signal peptide
was obtained via PCR amplification of tPAsp-Tp9 from pTP9
using SmaI-NheI Tp9 sense and Tp9 AU1 antisense primers
(Supplementary Table 1). The PCR amplification reaction was
carried out as described above. The amplicon was cut with
SmaI and cloned into the PmeI linearized pWPI commercial
vector (Addgene).
Transient Transfection and Secretion of
Tp9 From HEK 293T Cells
To evaluate the expression and secretion of Tp9, HEK
293T cells were transiently transfected with pCMV-Tp9AU1,
pCMV-1spTp9AU1, pCMV-tPAspTp9AU1, pEF1α-tPA-Tp9-
iresGFP, pCMV-Tp9spGFP, pEF1α-GFP (pWPI, Addgene), and
pCMV-GFP (pEGFP-C1, negative control, Clontech) using
Polyethylenimine (PEI) transfection reagent (Polysciences, Inc.).
Briefly, cells were seeded at 3× 105 cells/well in 6-well plates and
incubated overnight at 37◦C/5% CO2 in a humidified incubator.
Cells were then incubated for 6 h with a transfection mix
containing 3 µg plasmid DNA and PEI (ratio 1:2.5 DNA-PEI)
in Dulbecco’s modified essential medium (DMEM) high glucose
(Euroclone) without serum. After incubation, the transfection
mix was replaced by fresh medium EMEM, with 10% FBS, 100
IU/ml of penicillin, 100µg/ml of streptomycin and 0.25µg/ml
of amphotericin B, and incubated for 24 h at 37◦C/5% CO2 in a
humidified incubator. To test supernatant protein expression, the
transfection solution was replaced with fresh DMEM/F12 (ratio
1:1)mediumwithout FBS and incubated for 48 h at 37◦C/5%CO2
in a humidified incubator. Cell supernatant was then collected
and analyzed by immunoblot.
Lentivirus Reconstitution and Transduction
HEK 293T cells were transfected in a T175 cm2 flask with 25
µg of pEF1α-tPA-Tp9-iresGFP transfer vector, 13 µg of p8.74
packaging vector, 10 µg of pMD2 pseudotyping vector, and
10 µg of pREV using PEI transfection reagent (Polysciences,
Inc.). Briefly, 58 µg of DNA were mixed with 145 µg of
PEI (1 mg/mL) (ratio 1:2.5 DNA-PEI) in 3ml of Dulbecco’s
modified essential medium (DMEM) high glucose (Euroclone)
without serum. After 15min incubation at room temperature,
4x volumes of medium without serum were added and the
transfection solution transferred to the cell monolayer and left for
6 h at 37◦C/5% CO2, in a humidified incubator. The transfection
mixture was then replaced with 25ml of fresh medium EMEM
supplemented with 10% FBS, 50 IU/ml of penicillin, 50µg/ml
of streptomycin and 2.5µg/ml of amphotericin B and cells
incubated for 48 h at 37◦C/5% CO2. The flask was then stored
at −80◦C. Lentivirus was later obtained by subjecting cells to
three freeze-thaw cycles, and then clarifying the supernatant
via centrifugation at 3,500 rpm for 5min at 4◦C and filtering
through a 0.45µm filter (Millipore). The clarified supernatant
was stored at −80◦C. To obtain stably transduced cell lines,
1 × 105 HEK 293T cells were infected with 2 × 105 TU
(transducing units) of reconstituted tPA-Tp9AU1 lentivirus. Cells
were incubated overnight at 37◦C/5% CO2 and the culture
medium was then replaced with fresh medium supplemented
with 10% of FBS. Transduced cells were observed daily via
fluorescence microscopy for GFP expression to monitor the
rate of transduction. ADSSC, BBMSC, EADSC, MDCK, and
PK15 were similarly transduced. All the tPA-Tp9AU1 lentivirus
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transduced cell lines were detached, washed twice with sterile
PBS, suspended in PBS, and subjected to analysis with a Tali
image cytometer (Invitrogen) to assess transduction rate.
Cattle, T. parva Infection, and
Ethics Statements
This study was carried out in accordance with the
recommendations of The U.S. AnimalWelfare Act (United States
Code, Title 7, Chapter 54, sections 2131–2159) and Animal
Welfare Regulations (Code of Federal Regulations, Title 9,
Chapter 1, Subchapter A, parts 1–4). The protocol was approved
by the Washington State University Institutional Animal Care
and Use Committee, protocol number 4980. Therapeutic drugs
were administered according to the manufacturer’s dosing
instructions. Six MHC class I A10 or A14 haplotype-matched
(27) Holstein-Friesian steer calves obtained at 3–6 months of
age were utilized in this study. Pre-infection complete blood
counts (CBCs) were normal, and all calves tested negative on a
pre-infection T. parva PIM enzyme-linked immunosorbent assay
(ELISA) as previously described (28). Four steers (#139, #147,
#152, and #158) were infected with a T. parva Muguga stabilate
and concomitantly treated with oxytetracycline as previously
described (29). Beginning 3 days after ITM, the temperature,
pulse, respiratory rate, and CBC were monitored daily for
each animal. Steers that developed significant pyrexia (rectal
temperature >40.2◦C) were treated with flunixin meglumine,
and those that developed dyspnea were treated with furosemide
and buparvaquone. Animals were re-infected three more times
at 6 month intervals, and were monitored for adverse reactions
as above for each infection; however, no adverse clinical signs
were detected during subsequent infections. Maintenance and
boosting of T. parva immunity was verified by PIM ELISA. The
remaining two steers (#141 and #1413) were used as uninfected
negative controls. PBMC and serum samples from each steer
were used for cellular and serological assays to investigate the
antigenicity of Tp9.
Immunoblot
Protein cell extracts were obtained from pCMV-Tp9AU1,
pCMV-1spTp9AU1, pCMV-tPAspTp9AU1, pEF1α-tPA-Tp9-
iresGFP, pCMV-Tp9spGFP, and pCMV-GFP transfected HEK
293T, or from tPA-Tp9AU1 lentivirus stably transduced ADSSC,
BBMSC, EADSC, HEK 293T, MDCK and PK15 and un-
transduced control cell lines by adding 100 µl of cell extraction
buffer (50mM Tris-HCl, 150mM NaCl, and 1% NP-40; pH 8).
After BCA total protein quantification (PierceTM BCA Protein
Assay kit, Thermo Fisher Scientific), cell extracts containing 5, 10,
or 20µg of total protein were electrophoresed through 10% SDS-
PAGE. After that, proteins were transfer into nylon membranes
by electroblotting, membranes were incubated with anti-AU1
rabbit polyclonal antibody (A190-125A, Bethyl laboratories
Inc.) diluted 1:10.000, and then with a secondary antibody
goat anti-rabbit immunoglobulin labeled with horse radish
peroxidase (Sigma), diluted 1:15.000 to be visualized by enhanced
chemiluminescence (Clarity Max Western ECL substrate, Bio-
Rad). Also, cell supernatants, obtained from HEK 293T
transfected with pCMV-Tp9AU1, pCMV-1spTp9AU1, pCMV-
tPAspTp9AU1, pEF1α-tPA-Tp9-iresGFP, pCMV-Tp9spGFP, and
pCMV-GFP and from all the transduced cell lines, were collected
after 48 h in serum free medium DMEM-F12 secretion condition
and analyzed through 10% SDS-PAGE gel electrophoresis and
immunoblotting as described above.
Tp9 ELISA
Serum samples from T. parva-immune and control cattle were
used to evaluate the antigenicity of the mammalian expressed
and secreted Tp9 by ELISA. Briefly, microplates (Immulon R©
Microtiter
TM
, Thermo Fisher Scientific) were coated overnight at
4◦C with 500 ng/well of HEK 293T cell supernatant containing
Tp9 or GFP in 1x ELISA coating buffer (BioLegend). After
blocking in 20% non-fat milk, serum samples diluted 1:100
were added to each well and the plate incubated for 1 h at
room temperature. Mouse anti-AU1monoclonal antibody (clone
G8-D3, 1:200, Creative Diagnostics) was used as a control to
verify binding of recombinant Tp9-AU1 to the ELISA plates.
After 3 washes in 20% (v/v) Tween-20 in PBS (PBS-T), anti-
bovine (1:5,000) (Jackson ImmunoResearch) or anti-mouse
(1:5,000) (Abcam) IgG-HRP was added to each well, and the
plates incubated for 1 h at room temperature. Plates were then
washed three times in PBS-T and developed with TMB substrate
(Thermo Fisher Scientific). The enzymatic reaction was stopped
by adding 0.2MH2SO4 to each well, and the plates read at 450 nm
using an ELISA plate reader (MultiSkan MCC, Thermo Fisher
Scientific). Results of the Tp9 ELISA are presented as normalized
OD450 where the OD of the wells containing supernatant from
HEK 293T cells transfected with pEF1α-GFPwas subtracted from
the OD of the wells containing the Tp9 supernatant. Serum
samples from T. parva infected and uninfected control animals
were also tested for the presence of anti-PIM antibodies by ELISA
as previously described (28).
Generation of T. parva-Infected
Lymphocyte Cell Lines
T. parva infected lymphocyte cell lines were established and
maintained as previously described (30). Briefly, PBMC were
isolated from whole blood using Histopaque R© (Sigma) and 4 ×
107 cells were incubated with 500µlT. parva (Muguga sporozoite
stabilate P2015/4) for 90min at 37◦C/5% CO2. Cells were gently
mixed every 15min during the incubation. After incubation, cells
were washed in 15ml of cRPMI (10% fetal bovine serum, 24mM
of HEPES, 2mM of L-glutamine and 10µg/mL of gentamicin)
and plated at 2 × 106 cells/well in 24-well cell culture plates.
Cells were cultured in cRPMI at 37◦C/5% CO2 and infection
was assessed by intracellular staining the cells with the anti-PIM
monoclonal antibody ALS40 (13) followed by flow cytometric
analysis. Once established, cell lines were maintained at 37◦C/5%
CO2 and sub-cultured in fresh cRPMI every 2–4 days as needed.
Bovine IFNγ ELISpot
PBMC from T. parva-immune and uninfected control cattle were
isolated as described above and exposed to recombinant Tp9
secreted from pEF1α-tPA-Tp9-iresGFP transfected HEK 293T
cells. Production of IFNγ by PBMCwas measured using ELISpot
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(MabTech) following the manufacturer’s instructions. Briefly, 1
× 105 PBMC were added to MultiScreen R© HTS 96-well plates
(Millipore) coated overnight with anti-bovine IFNγ capture
antibody (MT17.1, 10µg/ml). Cells were incubated overnight
at 37◦C/5% CO2 in a humidified incubator with supernatant
from HEK 293T cells transfected with pEF1α-tPA-Tp9-iresGFP
or pEF1α-GFP. To optimize the amount of recombinant protein
to use in the ELISpot assays, a preliminary experiment in
which PBMC were exposed overnight to HEK 293T supernatant
containing 1, 10, 50, or 100 ng of Tp9 and IFNγ ELISpot
performed. Optimal IFNγ production and minimal cell toxicity
were obtained using supernatant containing 10 ng of Tp9 (data
not shown) and this amount was then used throughout the study.
PBMC from immune and control cattle were also stimulated
with T. parva schizont-infected cell line lysate (20 µl lysate
per well, ∼1.5 × 105 T. parva infected cell equivalents per
well) and 20 ng/ml phorbol 12-myristate 13-acetate (Sigma)
plus 1µg/ml Ionomycin (Millipore) as positive controls for T.
parva specific immune responsiveness and IFNγ production,
respectively. After incubation, ELISpot plates were washed five
times in PBS and incubated for 2 h with biotinylated anti-bovine
IFNγ detection antibody (MT307, 0.25µg/ml). Plates were again
washed five times in PBS, incubated for 1 h with streptavidin-
alkaline phosphatase conjugate (1:1,000) (MabTech), washed five
more times in PBS and developed using the substrate for ELISpot
assay BCIP/NBT-plus (MabTech). ELISpot plates were read
and analyzed using an Immunospot R© ELISpot reader (Cellular
Technology Limited).
Blockage of MHC Class I and Class II
To investigate the role of MHC class I and class II in IFNγ
production, blocking experiments were performed as previously
described (31). Briefly, PBMC were isolated as described above
and incubated for 15min at 4◦C with a pool of anti-bovine
MHC class I and class II monoclonal antibodies (mAb) (1
µg mAb/106 cells) (Supplementary Table 2). Cells were washed
once in cRPMI, incubated with recombinant Tp9, and IFNγ
ELISpot performed as describe above.
Cell Depletion
Following PBMC isolation as described above, depletion of
CD4, CD8, or γδ T cells was performed to allow better
characterization of the Tp9-specific cellular immune response.
Monoclonal antibodies to bovine CD4, CD8, TCR δ chain
FIGURE 1 | Tp9 expression and secretion by mammalian cells. Server (Phobius) output prediction of transmembrane topology and signal peptides from the
amino acid sequence of Tp9 protein (A). A diagram (not on scale) of Tp9 protein subcellular localization as predicted by a different server (Protter) (B). Immunoblot of
pCMV-Tp9AU1 transfected HEK 293T cells supernatant and mock pCMV-GFP transfected HEK 293T cells supernatant. Lanes were loaded with different amounts of
serum free medium supernatant (5, 10, and 20 µl) at 48 h post transfection. The same number HEK 293T cells were transfected with the same amount of
pCMV-Tp9AU1 or pCMV-GFP DNA and with the same efficiency of transfection (C). Immunoblot of serum free medium supernatant and protein extract from
pCMV-1spTp9AU1 transfected HEK 293T cells. Supernatant lanes were loaded with different amounts of serum free medium supernatant (5, 10, and 20 µl), whereas
pellet lanes were loaded with different amounts of protein extract (5, 10, and 20 µg) (D). Immunoblot of pCMV-Tp9spGFP transfected HEK 293T cell supernatant and
mock pCMV-GFP transfected HEK 293T cell supernatant. Lanes were loaded with different amounts of serum free medium supernatant (5, 10, and 20 µl) at 48 h post
transfection. The same number HEK 293T cells were transfected with the same amount of pCMV-Tp9spGFP or pCMV-GFP DNA and with the same efficiency of
transfection (E).
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(Supplementary Table 2) were used with MACS R© MicroBeads
(Miltenyi Biotec) for depletion by following the manufacture’s
protocol. Briefly, cells were incubated with the monoclonal
antibody/ies specific for markers of the cell population(s) to
be depleted (1 µg mAb/106 cells) for 15min at 4◦C in MACS
buffer (PBS without Ca+2 and Mg
+
2 , pH 7.0, 0.5% BSA, and
2mM EDTA). Subsequently, cells were washed twice in MACS
buffer and incubated with goat anti-mouse IgG MicroBeads
(20 µl MicroBeads/107 cells) (Miltenyi Biotec) for 15min at
4◦C. Cells were then washed twice in MACS buffer and passed
through a MACS LS column (Miltenyi Biotec). Efficiency of
depletion was evaluated by flow cytometry using the Guava R©
easyCyteTM HT system (Millipore). CD4 depleted cells, CD8
depleted cells, or CD4/γδ depleted cells were used for IFNγ
ELISpot as described above.
RESULTS
Tp9 Secretion and Signal
Peptide Characterization
Although no functional data on the secretion of the Tp9 protein
have been published to date, it is predicted to be secreted due to
the presence of a signal peptide and the lack of a transmembrane
domain. In silico analysis revealed a putative Tp9 signal peptide
that, although highly conserved among Tp9 sequences from
different T. parva isolates, prompts only weak protein secretion
compared to canonical signal peptides of typical mammalian
secreted proteins. In fact, according to its amino acid sequence
and as predicted by two servers for signal peptide prediction and
visualization (Phobius; http://phobius.sbc.su.se/; and Protter;
http://wlab.ethz.ch/protter/start/), the signal peptide predictive
score of the putative Tp9 signal peptide is low (Figure 1A, red
line, score below 0.2; defined cut-off is 0.5), suggesting that
the protein is cytoplasmic and not secreted (Figures 1A,B, blue
line, score above 0.7; defined cut off is 0.5). However, Tp9 was
secreted from HEK 293T cells transfected with pCMV-Tp9AU1,
a construct delivering AU1 tagged Tp9 ORF, placed under
transcriptional control of the CMV promoter and the bovine
growth hormone polyadenylation signal (Figure 1C). Removal
of the signal peptide (pCMV-1spTp9AU1) completely abrogated
Tp9 secretion and the protein was retained inside the cells
(Figure 1D). Further, when the Tp9 signal peptide was placed
in front of GFP (pCMV-Tp9spGFP), it allowed GFP secretion
(Figure 1E). These data corroborate that Tp9 is a secreted protein
and possesses a functional signal peptide when it is expressed in
mammalian cells.
Tp9 Signal Peptide Substitution
Significantly Increases Protein Secretion
Since Tp9 contains a functional signal peptide, but was only
secreted from mammalian cells in small amounts, we sought
to determine if the substitution of the native signal peptide
FIGURE 2 | Impact of signal peptide substitution on Tp9 secretion by mammalian cells. Server (Phobius) output prediction of signal peptide from the first 24 amino
acid of Tp9 protein sequence (A) compared with the first 24 amino acid of human tPA protein sequence (B). Immunoblot of serum free medium containing secreted
Tp9 from pCMV-tPAspTp9AU1 or pCMV-Tp9AU1 transfected HEK 293T cells at 48 h post transfection. Each lane was loaded with different amounts of serum free
medium supernatant (5, 10, and 20 µl). The same number HEK 293T cells were transfected with the same amount of pCMV-tPAspTp9AU1 or pCMV-Tp9AU1 DNA
and with the same efficiency of transfection (100%) (C). Intensity of protein bands in the immunoblot shown in (C) was quantified by densitometry (ChemiDoc;
MPIMAGING SYSTEM, LAB SOFTWARE, BioRad) and displayed as a bar graph. Data were normalized as a folds of increased secretion, where pCMV-Tp9AU1 signal
was considered equal to 1 for each amount of serum free medium loaded (D). The experiment was repeated three times and statistical significance (p < 0.001) was
assessed by Student’s t-test.
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with a canonical eukaryotic signal peptide would increase
secretion efficiency. Thus, the Tp9 signal peptide was substituted
with the human tPA signal peptide, which has a considerably
higher signal peptide predictive score than the native Tp9
signal peptide according to the amino acid sequence as
predicted by Phobius (http://phobius.sbc.su.se/) (Figures 2A,B).
Indeed when HEK 293T cells were transfected with pCMV-
tPA-Tp9AU1 (Tp9 containing tPA signal peptide) (Figure 2C),
a 10-fold increase in secretion was observed compared to
cells transfected with pCMV-Tp9AU1 (Tp9 containing its
native signal peptide) (Figure 2D). Further, Tp9 was efficiently
secreted from different animal species cells lines transduced
with a replication-incompetent lentiviral vector delivering tPA-
Tp9AU1 (Figure 3A), as evidenced by efficient GFP production
(Figure 3B) and detection of AU1-tagged recombinant Tp9 in
cell supernatants by immunoblot (Figure 3C). This lentiviral
transfer vector, pEF1α-tPA-Tp9-iresGFP, carries Tp9 and GFP
under the transcriptional control of the human elongation
factor 1 alfa (EF1α) strong promoter; the GFP ORF was in a
bicistronic form with tPAsp-Tp9 through an Internal ribosomal
entry site (IRES). After the reconstitution of the replication
incompetent lentiviral particles in HEK 293T cells, various cell
lines constitutively secreting Tp9 into the medium supernatant
were generated as a useful Tp9 antigen source.
T. parva-Immune Cattle Produce
Antibodies That Recognize
Recombinant Tp9
Next we utilized HEK-cell-expressed, recombinant Tp9 to
determine if T. parva-immune cattle produce antibodies to this
antigen following infection (Figure 4). HEK cells were chosen
for expression due to significantly higher recombinant Tp9
protein secretion from this line compared to other cell lines
tested. An ELISA was developed using supernatant of HEK 293T
cells containing soluble, full-length, recombinant tPAspTp9 as
antigen. Individual wells containing supernatant of HEK 293T
cells transfected with a plasmid expressing GFP (pEF1α-GFP)
were used as a control to normalize the data. Serum samples from
T. parva-immune and control cattle were used in the Tp9 ELISA.
Results demonstrate the presence of anti-Tp9 IgG antibodies in
all four immune animals (Figure 4A).MeanOD values from each
of the immune animals were ≥ three standard deviations above
the mean OD values from each of the control cattle, indicating
the specificity of the assay.Mouse anti-AU1monoclonal antibody
was used to verify binding of Tp9-AU1 to the ELISA plates
(data not shown). To confirm T. parva-immune status, serum
samples from all cattle were also tested in an anti-PIM ELISA
as previously described (28) and as expected, the data showed
the presence of anti-PIM antibodies in all four infected animals
(Figure 4B). Significant anti-Tp9 and anti-PIM antibodies were
not detected in serum samples from control cattle.
Production of IFNγ by PBMC From T.
parva-Immune Cattle Following ex vivo
Exposure to Recombinant Tp9
To further characterize the antigenicity of recombinant Tp9
expressed in mammalian cells, PBMC from T. parva-immune
FIGURE 3 | Generation of stably transfected cells secreting Tp9. Diagram of
pEF1α-tPA-Tp9-iresGFP lentiviral transfer vector (not on scale) (A).
Representative images (10X) of pEF1α-tPA-Tp9-iresGFP transduced ADSSC,
BBMSC, HEK 293T, EADSC, MDCK, PK15 cells, and transduction efficiency
(T.E.) as measured by cytometry (TALI, Image based cytometer, Invitrogen) (B).
Immunoblot of serum-free medium at 48 h post collection from
pEF1α-tPA-Tp9-iresGFP stably transduced ADSSC, BBMSC, HEK 293T,
EADSC, MDCK, and PK15 cells. Each lane was loaded with different amounts
of serum free medium supernatant (5, 10, and 20 µl) (C).
cattle were exposed to soluble, secreted Tp9 and IFNγ production
evaluated by ELISpot (Figure 5). Significant numbers of PBMC
(p < 0.5) from two of four immune animals produced IFNγ
following exposure to Tp9 compared to cells in medium only
or cells exposed to supernatant from pEF1α-GFP transfected
HEK 293T cells (Figure 5A). As expected, significant numbers
(p < 0.5) of PBMC from all four immune cattle produced
IFNγ after exposure to T. parva cell line lysate (Figure 5A).
No significant IFNγ response was detected when PBMC from
uninfected animals were exposed to Tp9 or T. parva cell line
lysate compared to cells in medium only (Figure 5B).
Next we investigated potential mechanisms to explain the
variability of IFNγ production by PBMC from the T. parva-
immune cattle following exposure to recombinant Tp9. By
genotypingMHC class I and class II loci we found that steer #147,
one of the animals whose cells produced IFNγ in response to Tp9,
was homozygous A14/A14 for MHC class I and heterozygous
0902A/1401B for MHC class II. Steer #158, the other animal
whose cells produced IFNγ in response to Tp9, was heterozygous
for both MHC class I and class II, A10/A19 and 1001A/0101A,
respectively (Table 1). The two T. parva-immune steers whose
cells did not produce IFNγ following exposure to Tp9 were
Frontiers in Immunology | www.frontiersin.org 7 April 2019 | Volume 10 | Article 897
Bastos et al. Theileria parva Antigen 9 Characterization
FIGURE 4 | Humoral immune response to Tp9 in T. parva-immune animals. T. parva-immune cattle (#139, #147, #152, and #158) and uninfected animals (#141 and
#1413) were tested by a Tp9 ELISA and T. parva PIM ELISA. Presence of antibodies to Tp9 in T. parva-immune animals. Results are presented as normalized OD450
(Tp9 OD450—GFP OD450) (A). Results show the presence of anti-PIM antibodies in T. parva-immune animals (B). Dashed lines in (A,B) indicate 3 standard
deviations of the negative samples (B).
FIGURE 5 | IFNγ production from PBMC exposed to HEK 293T cell supernatant containing Tp9. T. parva cell line lysate and supernatant from HEK 293T cells
transfected with pCMV-GFP were used as positive and negative controls, respectively. Bar charts show the average of a representative experiment and results are
shown as spot forming units (SFU) per 105 PBMC of each animal. A representative ELISpot well is depicted on the top of each bar and numbers represent the total
number of IFNγ spots per well. Steers #147, #152, #139, and #158 were T. parva-immune animals (A). Steers #1413 and #141 were used as uninfected control
animals (B). *p < 0.05.
heterozygous for both MHC class I and class II. Steer #152
was A11/A14 and 0101A/1101A for MHC class I and class II,
respectively, and animal #139 was A10/A12 and 1001A/1501A
for MHC class I and class II, respectively (Table 1). When
the IFNγ ELISpot was repeated in the presence of a pool of
antibovine MHC class I and class II monoclonal antibodies,
IFNγ response was completely abrogated in steers #147 and
#158 (Figures 6A,B). Collectively, these results demonstrate that
PBMC from T. parva-immune cattle produce IFNγ following
ex vivo exposure to recombinant, mammalian-expressed Tp9,
consistent with anti-Tp9 cellular immune response development
during natural infection. Furthermore, these data also confirm
that the cellular immune response to Tp9 is MHC-restricted and
dependent on MHC genotypes.
CD4+ T Lymphocytes Are the Major Source
of IFNγ Following ex vivo Exposure to
Recombinant Tp9
We next sought to elucidate which lymphocyte population
was the primary source of IFNγ production following ex vivo
exposure to recombinant, mammalian expressed Tp9. In cattle,
IFNγ is primarily produced by CD4+ T cells, CD8+ T cells,
and γδ T cells in a MHC-restricted fashion, and to a lesser
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TABLE 1 | Genotype of MHC class I and class II of the Theileria parva-immune
animals used in this study.





extent by NK cells in a non-MHC-restricted manner (32–34).
Therefore, we performed depletion experiments followed by
ELISpot to determine which cell population(s) produce(s) IFNγ
in response to Tp9. MACS MicroBeads depletion of CD4+,
CD8+, or CD4+ and γδ T cells resulted in elimination of more
than 90% of the targeted population (data not shown). In steers
#147 and #158, PBMC populations depleted of CD8+ T cells and
stimulated overnight with recombinant Tp9 contained similar
numbers of IFNγ-producing cells as the total PBMC population
(Figures 6C,D). In steers #139 and #152, there was no significant
CD4+ T-cell IFNγ response to Tp9 (data not shown). In all
four steers, significant IFNγ-producing cells were not detected
in PBMC depleted of CD4+ T cells or CD4+ T cells and γδ T
cells compared total PBMC and cells stimulated with negative
control antigen (supernatant from HEK 293T cells transfected
with pEF1αGFP). Taken together, these results strongly suggest
that CD4+ T cells are the major source of IFNγ following
overnight exposure to Tp9 (Figures 6C,D).
DISCUSSION
In the present study we performed a molecular characterization
of Theileria parva antigen Tp9 and used a recombinant,
mammalian expressed Tp9 to study its antigenic properties in
cattle. Initially, we showed that native sequence of Tp9 presents
a functional, but atypical signal peptide. Interestingly, secretion
of Tp9 from mammalian cells was significantly increased by
replacing the native secretion signal by a canonical eukaryotic
signal peptide. Using this recombinant, full-length Tp9 secreted
from mammalian cells, we showed that T. parva-immune cattle
develop both humoral and cellular immune response to this
antigen. Our results also indicate that CD4+ T cells are the
major source of IFNγ following ex vivo exposure to recombinant,
mammalian-expressed Tp9.
ECF, the acute lymphoproliferative form of T. parva infection,
has a major economic impact on cattle production in endemic
areas of Eastern, Central, and Southern Africa (1, 35). Cattle
can be protected against ECF by ITM vaccination, where
animals are inoculated with live T. parva sporozoites and
simultaneously treated with a long-acting oxytetracycline (7,
29). ITM-vaccinated animals usually undergo an asymptomatic
infection, and develop long-lasting immunity to similar strains
of T. parva. In addition to ITM, cattle in endemic areas can
also be treated with acaricides to decrease infestation by the
Theileria parva tick vector, Rhipicephalus appendiculatus. Both
adoption of ITM vaccination and acaricide use are curtailed
by numerous financial, logistical and environmental drawbacks
and therefore, there is an urgent need for the development of
affordable, next-generation vaccines to control T. parva (35). To
achieve this goal, it is critical to discover and characterize new
T. parva candidate vaccine antigens and to optimize suitable
systems for recombinant antigen expression and delivery. In
the present study, we expressed and secreted full-length Tp9, a
recently-discovered, candidate T. parva vaccine antigen, using
a mammalian system and characterized its antigenic properties
in cattle.
Previous attempts to express recombinant T. parva proteins
in prokaryotic or eukaryotic systems for vaccine purposes have
been challenging and the process has been hindered due to
protein insolubility and misfolding, among other issues (15,
16, 20). Recently, we were able to express full-length T. parva
p67 antigen in mammalian cells and demonstrated that the
recombinant antigen retained its immunogenic properties (21).
Considering the technical and biological challenges associated
with the expression of Theileria sp. antigens, it is desirable
to develop a practical, systematic eukaryotic system to express
potential vaccine target antigens. In the present study, we
efficiently expressed full-length Tp9 in several mammalian
cell lines by either transfecting cells with pCMV-tPA-Tp9AU1
(Tp9 containing tPA signal peptide) or transducing cells
with a replication-incompetent lentiviral vector delivering tPA-
Tp9AU1. By cloning the tPA signal peptide upstream of the Tp9
gene, we were able to express and obtain efficient secretion of the
Tp9 antigen from all mammalian cell lines tested. The secreted
antigen was subsequently used for antigenic assessment. These
results demonstrate the plasticity and usefulness of the presented
expression system to produce antigens that can be further tested
in T. parva vaccine formulations.
Molecular analysis performed in this study demonstrated
that Tp9 contains a unique signal peptide with only moderate
activity in mammalian cells. By replacing the native Tp9 signal
peptide with the human tPA signal peptide, we achieved a 10-
fold increase in secretion of Tp9 from HEK cells. Apicomplexan
parasites have evolved specific molecular mechanisms to adapt
to their respective intracellular niches and interact with their
hosts (36). One of these mechanisms is the secretion and
trafficking of parasite proteins into the parasitophorous vacuole
and subsequently into host cell cytoplasm (37). However, in
contrast to other Apicomplexan parasites, such as Toxoplasma,
Cryptosporidium, and Plasmodium, T. parva does not form a
parasitophorous vacuole and resides free into the cytoplasm of
infected lymphocytes (38). A recent study demonstrated that the
T. annulata antigen Ta9, an ortholog of Tp9, does indeed localize
to the host cell cytoplasm, where it is involved in the activation
of the transcription factor AP-1, which leads to the expression
of cell proliferation genes (39). Here, we demonstrated that the
Tp9 signal peptide is only weakly functional to achieve secretion
in mammalian cells. However, it is likely that this signal peptide
functions effectively within the parasite to achieve secretion of
Tp9 into the cytoplasm of infected lymphocytes, where it may
interact with host signaling pathways.
As we demonstrated that transiently transfected cells secreted
Tp9 in the cell culture medium allowing the recovery of the
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FIGURE 6 | IFNγ production by cells from T. parva-immune cattle (steers 147 and 158), as measured by IFNγ ELISpot. Monoclonal antibody blockade of MHC class I
and class II molecules abrogates the IFNγ response to Tp9 in both T. parva-immune steers (A,B), indicating that the response to Tp9 is MHC-restricted. IFNγ
production by total PBMC, the CD4+ T-cell depleted cell population, and the CD8+ T-cell depleted cell population from T. parva-immune steers 147 (C) and 158
(D) stimulated overnight with recombinant Tp9. In both steers, significant responses are observed only in the total PBMC and CD8+ T-cell depleted populations,
suggesting that CD4+ T cells are the primary source of IFNγ production in T. parva-immune cattle. In all panels, results are shown as spot forming units (SFU) per 105
PBMC. ELISpot experiments were repeated 3 times, and samples tested in triplicate each time. *p < 0.05.
protein directly from cell supernatant, it was of interest to
generate stable cell lines constitutively secreting Tp9, as a
source of protein for various purposes. To achieve this, a third
generation, replication incompetent lentiviral vector delivering
tPAsp-Tp9 expression cassette was generated. After lentiviral
particles reconstitution, several cell lines from different animal
species, were transduced with an efficiency ranging of 86–
100%, measuring GFP expression by Tali assay. The level of
GFP expression in the tPAsp-Tp9AU1 lentiviral transduced cells
reflects the expression of Tp9 protein because Tp9 ORF is located
upstream of the IRES sequence in a bi-cistronic form with the
GFP ORF. Secreted Tp9 can be potentially purified from serum-
free medium of transduced cells and used for immunization and
immunological assays, without the need of further purification.
The bi-cistronically expressed GFP enables positive cells to be
sorted to increase the number of Tp9 secreting cells.
Two out of four T. parva-immune cattle in our study
had significant ex vivo cellular immune responses to Tp9,
consistent with development of an anti-Tp9 T-cell response
during infection. Numerous studies have shown that T cells
from T. parva-immune cattle produce IFNγ in response to
T. parva-infected cells and to a subset of T. parva antigens
(10, 40, 41). Immune protection against T. parva requires the
development of robust MHC class I and class II restricted
T-cell responses, and it is likely that efficient induction and
recall of such CD8T cell responses also requires CD4T cell
responses. Outbred cattle populations express diverse MHC
genotypes (42–45), and the antigenic specificities of T cells
against T. parva antigens vary between cattle of different MHC
genotypes, as demonstrated by our data on Tp9. MHC class
I and II antibody blockage abrogated the IFNγ response in
both animals, confirming that the response is MHC-restricted.
This indicates that a subset of the MHC class I and class II
molecules expressed by these cattle present Tp9 epitopes that
are subsequently recognized by T cells during T-cell response
priming in acute infection.
Not only did 2/4 T. parva-immune cattle in this study
exhibit a cellular immune response to Tp9, but all four animals,
representing various MHC class I and class II genotypes, had a
significant anti-Tp9 antibody response. Tp antigens, including
Tp9, were identified by screening CD8+ T cell lines from T.
parva- immune cattle (10, 18), and Tp9 was initially identified
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as a T. parva schizont-antigen. A recent proteomic study
reported that Tp9 is also expressed by T. parva sporozoites
(46). Considering that sporozoites are the T. parva stage that is
infectious to cattle, these results have implications for vaccine
development. After inoculation by ticks, sporozoites are only
briefly exposed to fluids, including immunoglobulins, prior
to entering bovine lymphocytes. It is likely that B cells are
exposed to Tp9 within the milieu of lysed and necrotic schizont-
infected cells found in various tissues later in disease. Although
further studies are required to localize Tp9 within both T.
parva sporozoites and schizont-infected lymphocytes, the fact
that an anti-Tp9 antibody response is generated during T. parva
infection in cattle of various MHC class I and II genotypes
provides rationale for further testing of the Tp9 antigen as a
component of a multivalent subunit vaccine for T. parva.
Development of protective, affordable vaccines is the most
cost-effective approach to control both animal and human
infectious diseases, especially those neglected conditions that
primarily affect people in developing regions of the world (47–
49). A majority of the cost associated with ECF morbidity
and mortality is borne by smallholder pastoralist farmers (7)
in sub-Sahara Africa. ITM, the most effective means of ECF
prevention, is expensive and logistically challenging. Therefore,
development of new vaccines to control ECF is urgently needed
to mitigate the effects of the disease. Here, we investigated
the molecular and antigenic properties of Tp9, a T. parva
candidate vaccine antigen expressed by sporozoite and schizont
parasite stages. Data show that T. parva-immune animals
develop both humoral and cellular immune responses to
Tp9 during infection. The demonstrated antigenicity of Tp9
provides rationale for further evaluation of the effectiveness
of this antigen as a component of a subunit vaccine to
control T. parva.
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